Whitefort Capital Files 13D on Arbutus Biopharma

TL;DR

**Whitefort Capital just filed a 13D on Arbutus Biopharma. Big player watching closely.**

AI Summary

Whitefort Capital Management, LP has filed a Schedule 13D on May 9, 2024, indicating a change in beneficial ownership of Arbutus Biopharma Corporation. The filing details their holdings and intentions regarding the company's securities.

Why It Matters

This filing signals a significant stakeholder's increased attention or potential influence over Arbutus Biopharma, which could impact the company's strategic direction or stock performance.

Risk Assessment

Risk Level: medium — Schedule 13D filings often precede activist campaigns or significant strategic shifts, introducing uncertainty for investors.

Key Players & Entities

• Whitefort Capital Management, LP (company) — Filing entity
• Arbutus Biopharma Corporation (company) — Subject company
• DAVID SALANIC (person) — Signatory for Whitefort Capital
• Joseph Kaplan (person) — Signatory for Whitefort Capital
• TEKMIRA PHARMACEUTICALS Corp (company) — Former name of Arbutus Biopharma

FAQ

From the Filing

0001193805-24-000619.txt : 20240509 0001193805-24-000619.hdr.sgml : 20240509 20240509080020 ACCESSION NUMBER: 0001193805-24-000619 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20240509 DATE AS OF CHANGE: 20240509 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Arbutus Biopharma Corp CENTRAL INDEX KEY: 0001447028 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 980597776 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D SEC ACT: 1934 Act SEC FILE NUMBER: 005-85963 FILM NUMBER: 24928665 BUSINESS ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 BUSINESS PHONE: 604-419-3200 MAIL ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS Corp DATE OF NAME CHANGE: 20110607 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20081003 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Whitefort Capital Management, LP CENTRAL INDEX KEY: 0001884931 ORGANIZATION NAME: IRS NUMBER: 820808818 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D BUSINESS ADDRESS: STREET 1: 12 E. 49TH STREET STREET 2: 40TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 2122594370 MAIL ADDRESS: STREET 1: 12 E. 49TH STREET STREET 2: 40TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 SC 13D 1 sc13d14125002_05062024.htm THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. ) 1 Arbutus Biopharma Corporation (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 03879J100 (CUSIP Number) DAVID SALANIC Joseph Kaplan WHITEFORT CAPITAL MANAGEMENT, LP 12 East 49th Street, 40th Floor New York, New York 10017 ELIZABETH GONZALEZ-SUSSMAN OLSHAN FROME WOLOSKY LLP 1325 Avenue of the Americas New York, New York 10019 (212) 451-2300 Patricia Olasker Davies Ward Phillips & Vineberg LLP 155 Wellington Street West Toronto, ON M5V 3J7 (416) 863-0900 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) May 2, 2024 (Date of Event Which Requires Filing of This Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☒. Note:   Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.   See § 240.13d-7 for other parties to whom copies are to be sent. 1               The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes ). CUSIP No. 03879J100 1 NAME OF REPORTING PERSON Whitefort Capital Master Fund, LP 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐ 3 SEC USE ONLY 4 SOURCE OF FUNDS WC 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ☐ 6 CITIZENSHIP OR PLACE OF ORGANIZATION Cayman